You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 11, 2025

CLINICAL TRIALS PROFILE FOR ILUVIEN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Iluvien

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00770770 ↗ Fluocinolone Acetonide Intravitreal Inserts for Vein Occlusion in Retina Terminated Alimera Sciences Phase 2 2009-05-01 This study will assess the safety and efficacy of FA Intravitreal Inserts in subjects with macular edema secondary to RVO.
NCT01304706 ↗ Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study Completed Alimera Sciences Phase 3 2011-04-01 This study will assess the safety and utility of the new inserter for the administration of ILUVIEN in subjects with diabetic macular edema.
NCT02359526 ↗ A Pilot Study on the Effect and Safety of Iluvien® in Chronic Diabetic Macular Edema Patients Completed Association for Innovation and Biomedical Research on Light and Image Phase 4 2014-10-01 To provide treating physicians with experience with ILUVIEN as well as monitoring its safety (and effectiveness) in a real-life chronic diabetic macular edema (DME) patients judged insufficiently responsive to available therapies.
NCT02424019 ↗ Phase 4 IOP Signals Associated With ILUVIEN® Unknown status Alimera Sciences Phase 4 2015-05-06 This study will assess the safety in patients treated with ILUVIEN, with primary focus on IOP.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Iluvien

Condition Name

Condition Name for Iluvien
Intervention Trials
Diabetic Macular Edema 5
Diabetic Macular Edema (DME) 1
Macular Edema 1
Retinal Vein Occlusion 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Iluvien
Intervention Trials
Macular Edema 8
Edema 7
Retinal Vein Occlusion 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Iluvien

Trials by Country

Trials by Country for Iluvien
Location Trials
United States 44
Puerto Rico 1
Portugal 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Iluvien
Location Trials
Georgia 3
Florida 2
Colorado 2
California 2
Arizona 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Iluvien

Clinical Trial Phase

Clinical Trial Phase for Iluvien
Clinical Trial Phase Trials
Phase 4 5
Phase 3 1
Phase 2/Phase 3 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Iluvien
Clinical Trial Phase Trials
Completed 3
Withdrawn 2
Terminated 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Iluvien

Sponsor Name

Sponsor Name for Iluvien
Sponsor Trials
Alimera Sciences 5
Association for Innovation and Biomedical Research on Light and Image 1
Johns Hopkins University 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Iluvien
Sponsor Trials
Industry 5
Other 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

ILUVIEN: Clinical Trials, Market Analysis, and Projections

Introduction to ILUVIEN

ILUVIEN, developed by Alimera Sciences, Inc., is a fluocinolone acetonide intravitreal implant designed to treat various ocular conditions, including diabetic macular edema (DME) and autoimmune uveitis. This article provides an update on the ongoing clinical trials, market analysis, and future projections for ILUVIEN.

Ongoing Clinical Trials: NEW DAY Study

One of the significant clinical trials currently underway is the NEW DAY study. This multicenter, single-masked, randomized, controlled trial aims to evaluate ILUVIEN as a baseline therapy for patients with DME.

  • Enrollment and Design: The study has completed enrollment with approximately 300 treatment-naïve or near-naïve DME patients across 42 sites in the U.S.[1][2].
  • Treatment Protocol: Patients are randomized to receive either ILUVIEN intravitreal implant or five injections of intravitreal aflibercept 2 mg at four-week intervals for the first 16 weeks. After the initial 16-week period, both groups are evaluated every four weeks and receive supplemental aflibercept injections as needed[1].
  • Primary and Secondary Outcomes: The primary outcome measure is the mean number of supplemental aflibercept injections needed during the trial. Key secondary endpoints include mean best corrected visual acuity (BCVA) score over time, time to first supplemental treatment, and measures of retinal thickness variability based on optical coherence tomography (OCT)[1].

Expected Outcomes and Impact

The NEW DAY study is anticipated to provide critical data that could change the current treatment paradigm for DME.

  • Data Release: Top-line data from the study is expected in early 2025, which Alimera believes will support ILUVIEN as a first-line treatment option, offering patients the potential for longer vision maintenance with fewer injections compared to current therapies[1][2].
  • Clinical Significance: The study's findings could demonstrate the benefits of using ILUVIEN early in DME treatment, aligning with previous PALADIN data that indicated earlier use of ILUVIEN results in better outcomes[1].

Other Clinical Trials: SYNCHRONICITY Study

In addition to the NEW DAY study, Alimera is also conducting the SYNCHRONICITY Study.

  • Focus: This prospective, open-label clinical study is evaluating the safety and efficacy of YUTIQ (another Alimera product) for the treatment of chronic, non-infectious uveitis affecting the posterior segment and related intraocular inflammation[2].
  • Design and Timeline: The study involves a two-year follow-up with an interim top-line six-month efficacy readout anticipated in the third quarter of 2024[2].

Market Analysis and Projections

Current Market Performance

ILUVIEN has been showing promising growth in the market.

  • Revenue Growth: In the third quarter of 2023, Alimera reported record net revenue of $23.4 million, with a significant increase in U.S. net revenue driven by the sales of ILUVIEN and YUTIQ. The demand for ILUVIEN in Q3 2023 was up 8% compared to Q3 2022[2].
  • Financial Outlook: Alimera expects to deliver over $100 million in net revenue and more than $20 million in Adjusted EBITDA in 2024, indicating strong financial prospects for ILUVIEN[2].

Future Market Projections

The market for ILUVIEN is expected to expand significantly in the coming years.

  • Market Size and Insights: A comprehensive report projects an increase in the utilization and sales of ILUVIEN from 2024 to 2032, driven by continued research and increased healthcare expenditure. This growth will bolster ILUVIEN's position in the market, particularly in treating autoimmune uveitis[3].
  • Regulatory and Developmental Activities: Key regulatory milestones and developmental activities are expected to support the expansion of ILUVIEN's indications, potentially broadening the number of patients it can treat. Alimera is actively evaluating indication expansion opportunities[2][3].

Competitive Landscape

While ILUVIEN is poised for growth, it will face competition in the market.

  • Emerging Therapies: The introduction of late-stage emerging therapies in the field of autoimmune uveitis treatment may pose significant competition to ILUVIEN. However, detailed market insights and strategic planning will help Alimera navigate this competitive landscape[3].

Patient Impact and Quality of Life

The clinical trials and market projections for ILUVIEN also highlight its potential impact on patient quality of life.

  • Patient-Reported Outcomes: The NEW DAY study includes patient-reported outcome measures to evaluate the effect of ILUVIEN on patients’ quality of life and level of functioning. This data will be crucial in understanding the broader benefits of ILUVIEN beyond clinical efficacy[1].

Key Takeaways

  • Clinical Trials: The NEW DAY study is a pivotal trial comparing ILUVIEN to anti-VEGF therapy in DME patients, with expected data release in early 2025.
  • Market Growth: ILUVIEN is expected to see significant market growth driven by increased healthcare expenditure and ongoing research.
  • Financial Outlook: Alimera anticipates strong revenue and Adjusted EBITDA growth in 2024, supported by the sales of ILUVIEN and YUTIQ.
  • Patient Impact: ILUVIEN has the potential to improve patient quality of life by offering a treatment option that maintains vision longer with fewer injections.

FAQs

What is the NEW DAY study, and what is its primary objective?

The NEW DAY study is a multicenter, single-masked, randomized, controlled trial designed to evaluate ILUVIEN as a baseline therapy for patients with diabetic macular edema (DME). The primary objective is to compare the mean number of supplemental aflibercept injections needed between patients treated with ILUVIEN and those treated with anti-VEGF therapy.

When is the top-line data from the NEW DAY study expected to be released?

Top-line data from the NEW DAY study is expected to be released in early 2025[1][2].

How does ILUVIEN compare to current standard treatments for DME?

ILUVIEN is being evaluated as a potential first-line treatment that could maintain vision longer with fewer injections compared to current anti-VEGF therapies[1].

What other clinical trials is Alimera conducting related to ILUVIEN or similar products?

Alimera is also conducting the SYNCHRONICITY Study to evaluate the safety and efficacy of YUTIQ for the treatment of chronic, non-infectious uveitis[2].

What are the projected market trends for ILUVIEN from 2024 to 2032?

The market for ILUVIEN is expected to grow significantly from 2024 to 2032, driven by continued research, increased healthcare expenditure, and potential expansion of indications[3].

How will ILUVIEN impact patient quality of life?

ILUVIEN is expected to improve patient quality of life by offering a treatment option that maintains vision longer with fewer injections, as well as by reducing the need for frequent clinic visits and injections[1].

Sources

  1. Alimera Sciences, Inc. - "Alimera completes recruitment for its NEW DAY study" - Ophthalmology Times, May 24, 2023.
  2. BioSpace - "Alimera Sciences Reports Third Quarter 2023 Results" - BioSpace, October 26, 2023.
  3. GlobeNewswire - "Comprehensive Report on ILUVIEN for Autoimmune Uveitis Reveals Market Size Insights and Forecast to 2032 in Key European Markets" - GlobeNewswire, July 17, 2024.
  4. pSivida Corp. - "pSivida's Iluvien Phase III Study passes final DSMB Review" - pSivida Corp., April 9, 2009.
  5. Simply Wall St - "New Clinical Trials Will Expand ILUVIEN And YUTIQ Market Presence In 2025" - Simply Wall St, September 15, 2024.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.